Advance ZincTek (ASX:ANO) lifts pre-tax profit 13% as enquiry pipeline builds

Revenue climbed 12.65% to $13.1m and management is flagging enquiry volumes well above the prior year

Advance ZincTek (ASX:ANO) has told the market it expects unaudited pre-tax profit of $2.294 million for FY26, up 13% on the $2.029 million booked in FY25. Sales revenue is expected to land at $13.111 million, a 12.65% increase on the prior year.

For a small cap zinc oxide specialist that has spent years hunting scale, the important thing is not the absolute number. It is that revenue and profit have moved in the same direction, at roughly the same pace, without margins going sideways.

The other line worth reading twice sits further down the release. Management is flagging global enquiries well above the prior corresponding period. That is a leading indicator, and for a company selling into cosmetics, sunscreen and coatings markets, it is arguably more valuable than the FY26 print itself.

The question for investors is whether this is the beginning of an operating leverage story, or another year of steady but modest growth in a niche that never quite breaks through. On today’s numbers the balance tips slightly toward the former, but not decisively.

Revenue and profit growing in lockstep is the number that actually matters

Revenue up 12.65% and pre-tax profit up 13% is not a coincidence. It suggests operating costs have been held roughly flat as sales have grown, which is what you want to see in a specialty chemicals business with fixed manufacturing overhead.

The company sells zinc oxide products, primarily its ZinClear range, into personal care markets globally. These are relatively high margin ingredients where the win comes from consistent quality and regulatory approvals rather than commodity pricing.

That the profit growth just edged past revenue growth points to modest operating leverage kicking in. It is not dramatic, but at this scale, incremental margin expansion is how the equity story eventually rerates.

The enquiry pipeline is the leading indicator investors should be tracking

Management has specifically called out that global enquiries are well above the prior corresponding period. That is deliberate language and it is the part of the release doing the real work.

For a business selling technical ingredients into formulators and brand owners, enquiries convert to samples, samples convert to qualifications, and qualifications eventually convert to purchase orders. The lag can be 12 to 18 months.

We think the enquiry commentary matters more than the FY26 headline because it sets up FY27. If conversion rates hold, the revenue line in the next print should show visible acceleration rather than the mid-teens growth reported today.

What the unaudited tag means and where the risks still sit

These numbers are unaudited management accounts and subject to year-end audit procedures. In practice, revisions at audit for a business this size are usually minor, but investors should not treat the figures as final until the audited accounts land.

The bigger risks are structural rather than accounting. The company remains small, concentrated in a specialised ingredient category, and exposed to customer concentration and currency swings in export markets.

Our concern is that enquiry momentum has been flagged before in this name without translating into a step change in revenue growth. The next set of accounts, and specifically the conversion of those enquiries into contracted volumes, is the real test.

The Investors Takeaway for Advance ZincTek

The FY26 print is a solid, unspectacular result that shows the business is compounding quietly rather than breaking out. Revenue up 12.65% and pre-tax profit up 13% is exactly the kind of number that keeps the equity story alive without forcing a rerating.

The real signal is buried in the enquiry commentary. If those enquiries convert at anything close to historical rates, FY27 revenue growth should visibly accelerate from here, and the operating leverage picture becomes more compelling. If they do not, this remains a steady niche player with a modest earnings base.

Investors can find more in-depth coverage of ASX-listed specialty chemicals and small cap names at stocksdownunder. For now, we would want to see the next quarterly cash flow statement confirm the enquiry pipeline is translating into actual receipts.